CAS: 1639208-54-0; (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1-A]Isoquinolin-2-Yl 2-Amino-3-Methylbutanoate Bis(4-Methylbenzenesulfonate)

(S)-2-Benzyloxycarbonyl-Amino-3-Methylbutyric Acid-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-A]Isoquinolin-2-Yl Ester 以85的收率获得缬苯那嗪甲苯磺酸盐
参考文献:Wo2008058261A1
标题:Wo2008058261A1

专利信息

专利号:US-2024239791-A1
优先权日:2021-04-26
标题 :Processes for the synthesis of valbenazine
发明人：TUCKER JOHN LLOYD
权利人:NEUROCRINE BIOSCIENCES INC
摘要:The present application relates to processes for preparing (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of vesicular monoamine transporter 2 (VMAT2) useful in the treatment of hyperkinetic movement disorders such as tardive dyskinesia (TD).

专利号:US-2022363680-A1
优先权日:2019-09-13
标题 :Processes for the synthesis of valbenazine
发明人：TUCKER JOHN; KUCERA DAVID; HETTINGER DONALD; COCHRAN BRIAN M; BRANUM SHAWN; LE JACKIE; MCGEE KEVIN
权利人:NEUROCRINE BIOSCIENCES INC
摘要:The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b -hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of vesicular monoamine transporter 2 (VMAT2) useful in the treatment of hyperkinetic movement disorders such as tardive dyskinesia (TD).

专利号:WO-2022232060-A1
优先权日:2021-04-26
标 题:Processes for the synthesis of valbenazine

专利号:EP-4330255-A1
优先权日:2021-04-26
标题 :Processes for the synthesis of valbenazine

专利号:CN-114423755-A
优先权日:2019-09-13
标 题:Process for the synthesis of valbenazines

专利号:US-11806326-B2
优先权日:2018-01-29
标 题 :Methods for dopamine modulation in human neurologic diseases
发明人：SACKNER-BERNSTEIN JONATHAN
权利人:SACKNER BERNSTEIN JONATHAN
摘要:A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neuro-transmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).